secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001493152-23-000908
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports preliminary Q4 2022 revenue of ~$10.2-10.4M, up 12% YoY; FY2022 record $28.7-28.9M
--------------------------------------------------------------------------------

- Preliminary Q4 2022 revenue $10.2-10.4M, an increase of approximately 12% vs Q4 2021.
- Full year 2022 revenue of $28.7-28.9M, a record high and up ~20% compared to 2021.
- CEO Erica Monaco cites continued expansion of Ameluz-PDT for actinic keratosis as driver.
- Final Q4 and FY2022 financial results expected in March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/0001493152-23-000908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer